Polyrizon Ltd. submitted amended claims in its U.S. patent application, expanding protection for its intranasal drug delivery platform to include drug delivery systems and methods of use.
Key takeaways
Submitted amended claims expanding U.S. patent scope to cover mucoadhesive compositions, drug delivery systems, and methods of use.
Expanded claims include sulfated polysaccharide polymers forming uniform films for improved API delivery via mucosal contact.
Platform features prolonged residence time, improved bioavailability, controlled film formation, and versatility across drug types.
CEO Tomer Izraeli stated this strengthens IP protection and enhances platform value across therapeutic areas.
Aligns with strategy to strengthen global intellectual property portfolio.